231 related articles for article (PubMed ID: 20425376)
21. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Kluin-Nelemans HC; Coenen JL; Boers JE; van Imhoff GW; Rosati S
Blood; 2008 Aug; 112(4):1039-41. PubMed ID: 18502831
[TBL] [Abstract][Full Text] [Related]
22. Treatment strategies for peripheral T-cell lymphomas.
Foss FM
Best Pract Res Clin Haematol; 2013 Mar; 26(1):43-56. PubMed ID: 23768640
[TBL] [Abstract][Full Text] [Related]
23. Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG; Hallek M
Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
[TBL] [Abstract][Full Text] [Related]
24. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
25. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
27. [Recent advance in peripheral T-cell lymphoma, not otherwise specified].
Zhan HQ; Li XQ; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):353-6. PubMed ID: 20654164
[No Abstract] [Full Text] [Related]
28. Peripheral T-cell lymphoma.
Foss FM; Zinzani PL; Vose JM; Gascoyne RD; Rosen ST; Tobinai K
Blood; 2011 Jun; 117(25):6756-67. PubMed ID: 21493798
[TBL] [Abstract][Full Text] [Related]
29. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
30. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
Zhu WM; Li Y; Yu C; Li N; Li JS
Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
[No Abstract] [Full Text] [Related]
31. Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas.
Horwitz SM
Hematology Am Soc Hematol Educ Program; 2008; ():289-96. PubMed ID: 19074098
[TBL] [Abstract][Full Text] [Related]
32. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies.
Karlin L; Coiffier B
Semin Hematol; 2014 Jan; 51(1):25-34. PubMed ID: 24468313
[TBL] [Abstract][Full Text] [Related]
33. Novel therapies in peripheral T-cell lymphomas.
O'Leary HM; Savage KJ
Curr Oncol Rep; 2008 Sep; 10(5):404-11. PubMed ID: 18706268
[TBL] [Abstract][Full Text] [Related]
34. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
35. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
Savage KJ; Chhanabhai M; Gascoyne RD; Connors JM
Ann Oncol; 2004 Oct; 15(10):1467-75. PubMed ID: 15367405
[TBL] [Abstract][Full Text] [Related]
36. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
Tobinai K
Semin Hematol; 2010 Apr; 47 Suppl 1():S5-7. PubMed ID: 20359583
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab in CLL and other lymphoid neoplasms.
Ravandi F; O'brien S
Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
Wong ET
Expert Opin Pharmacother; 2005 Jun; 6(7):1107-14. PubMed ID: 15957965
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
Treon SP; Soumerai JD; Hunter ZR; Patterson CJ; Ioakimidis L; Kahl B; Boxer M
Blood; 2011 Jul; 118(2):276-81. PubMed ID: 21566092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]